It is made available under a CC-BY 4.0 International license .

- 1 Prevalence, treatment, and factors associated with cryptococcal meningitis post introduction
- 2 of integrase inhibitors antiretroviral based regimens among people living with HIV in
- 3 Tanzania
- 4 Makyao Minja<sup>1</sup>, Tusaligwe Mbilinyi<sup>2</sup>, Bryceson Mkinga<sup>3</sup>, Erick G. Philipo<sup>4</sup>, Joyce Owenya<sup>5</sup>, and
- 5 Manase Kilonzi<sup>1\*</sup>
- 6 *Affiliations*
- 7 <sup>1</sup>Department of Clinical Pharmacy and Pharmacology, School of Pharmacy, the Muhimbili
- 8 University of Health and Allied Sciences, Dar es Salaam, Tanzania.
- <sup>9</sup> <sup>2</sup>Department of Pharmaceutical Microbiology, School of Pharmacy, the Muhimbili University of
- 10 Health and Allied Sciences, Dar es Salaam, Tanzania.
- <sup>3</sup>Department of Pharmacognosy, School of Pharmacy, the Muhimbili University of Health and
- 12 Allied Sciences, Dar es Salaam, Tanzania.
- <sup>4</sup>Department of Pharmaceutics and Pharmacy Practice, School of Pharmacy, the Muhimbili
- 14 University of Health and Allied Sciences, Dar es Salaam, Tanzania.
- <sup>5</sup>Department of Pharmacy, Temeke Regional Referral Hospital, Dar es Salaam, Tanzania.
- 16 Corresponding author: <u>manasekilonzi@gmail.com</u>, +255 688 045752
- 17
- 18
- 19
- 20

It is made available under a CC-BY 4.0 International license .

#### 21 Abstract

Objective: This study aimed to assess the prevalence of CM, treatment practice, and the associated
 factor's post-introduction of Tenofovir Lamivudine and Dolutegravir (TLD) regimen among
 PLHIV in Tanzania.

Methods: This was an analytical cross-sectional study, and the data was collected retrospectively in three public regional referral hospitals (RRHs) in Dar es Salaam, Tanzania. A total of 405 files of the PLHIV admitted in the medical wards on the TLD regimen from January 2019 to December 2022 were reviewed. The collected information includes patient demographic characteristics, Cryptococcal status, CD4 level at the time of CM diagnosis, status of using ART, CM treatment approach, and outcome. Data was analyzed using SPSS software version 23.

**Results:** Out of 405, the majority 267(65.9%) were female, 224(55.3%) were aged between 36 - 55 years, and 293(72.3%) married. ART defaulters were found to be 37(9.1%). The prevalence of CM was found to be 48(11.9%), out of which 42(87.5%) received fluconazole alone. ART defaulter and marital status significantly (p-value < 0.05) were associated with those who tested CM positive.</p>

36 **Conclusion:** The study found the prevalence of CM among PLHIV to be significantly high and 37 the majority were treated with fluconazole alone. ART defaulters and marital status were 38 significantly associated with one being CM positive. Responsible authorities and stakeholders 39 should enforce guideline adherence and PLHIV should be encouraged on medication adherence.

40 Keywords: Cryptococcal meningitis, Fluconazole, Triple therapy, Prevalence, Treatment,
41 Tanzania

42

It is made available under a CC-BY 4.0 International license .

#### 43 I. Introduction

Cryptococcal Meningitis (CM) is one of the leading causes of laboratory-confirmed meningitis in 44 adults living in countries with a high burden of HIV especially in Sub-Saharan Africa (SSA) [1,2]. 45 46 CM accounts for over 100,000 incident cases of meningitis per year in the SSA [3]. The burden of CM in PLHIV is high and globally is estimated to cause 15%-20% of HIV-related deaths. In low-47 income countries (LICs) 220,000 cases of CM are estimated per year resulting in 181,000 deaths 48 [4]. In Tanzania, reports have shown that cryptococcosis has 50% fatality at any dose of antifungal 49 given [5]. CM is an opportunistic fungal infection usually affecting immune-compromised hosts 50 like People Living with Human Immune-deficiency Virus (PLHIV), diabetic patients, solid organ 51 transplant recipients, and patients receiving immunosuppressant [6]. The infection is not 52 transferred from person to person, but results from the inhalation of infectious spores mainly found 53 in bird droppings, that multiply in the lungs and can spread to the membranes covering the brain 54 and spinal cord causing meningitis [7]. In HIV-infected patients, the disease is considered as a 55 result of recurrence of latent infection which occurs months to years after the initial exposure event 56 57 [8,9].

In 2019, Tanzania introduced a Dolutegravir (DTG) based regimen of TLD as the preferred first-58 59 line antiretroviral therapy (ART) for most adults and adolescents for HIV-1 infections [10]. From 60 the two landmark clinical trials named ADVANCE and NAMSAL performed in SSA, the efficacy of DTG, and non-emergence of resistance support its use as a first-line regimen for ART-naïve 61 62 adults with HIV-1 [11]. Patients on the DTG-based regimen had high weight and the viral load 63 was suppressed more quickly compared to the Efavirenz-based regimen [12]. TLD is affordable 64 and well tolerated and improves the clinical outcomes of patients) [13,14]. On the other hand, triple 65 therapy of Amphotericin B, flucytosine (5-FC), and fluconazole is recommended for the treatment

It is made available under a CC-BY 4.0 International license .

of CM. The guidelines recommend two weeks of amphotericin B and 5-FC for the induction phase,
followed by fluconazole for the merging and maintenance phases of treatment [15]. Studies report
that the use of fluconazole alone is inferior and is associated with high morbidity and mortality
compared to triple therapy [16]. However, despite advances in HIV, and CM management, the
majority of PLHIV-living LICs face hospital acute mortality in the range between 30-50% [17].

Other factors associated with the burden of CM among PLHIV are reported to be; Being ART naïve and ART defaulter, being male, living in rural areas, being hospitalized, having low CD4 count, and having increasing age with CD4<100 cells, and having body mass index of <18.5kg/m<sup>2</sup>[18]. Making age, gender, body mass index, and ART adherence major determining factors for cryptococcal infection among PLHIV [19].

Similar to other World Health Organization (WHO) member states, Tanzania adopted the use of a 76 integrase inhibitors-based ART regimen as first-line therapy for adults with PLHIV, and through 77 its guidelines, triple therapy was introduced for the management of CM. Despite the efforts made 78 by the WHO and its member states, the majority of deaths among PLHIV are associated with CM 79 [20]. However, there is a scarcity of information with regard to the prevalence of CM and treatment 80 practice's post-introduction of integrase inhibitors-based regimens as first-line therapy for PLHIV 81 in LICs. Therefore, this study aims to determine the prevalence, treatment practice, and associated 82 factors of CM among PLHIV post-introduction of TLD in Dar es Salaam, Tanzania. 83

84

### II. Materials and Methods

A.

85

#### Study design and area

This was a hospital-based cross-sectional study using a retrospective data collection approach.
Data were collected from March to June 2023 in public regional referral hospitals (RRHs) in Dar

It is made available under a CC-BY 4.0 International license .

es Salaam, Tanzania i.e., Temeke, Amana, and Mwananyamala referral hospitals. The chosen
hospitals have Care and Treatment Centers (CTC) that serve the majority of PLHIV residing in
Dar es Salaam city and surrounding areas.

91 **B.** 

# Study population

People Living with HIV (PLHIV) admitted to the medical wards on TLD from 2019 to 2022 in
the three RRHs (Temeke, Amana, and Mwananyamala).

#### 94 C. Sample size and sampling technique

A minimum sample size of 153 PLHIV was estimated using the formula for cross-sectional study ( $n = p(1-p) z^2/d^2$ ). Assuming a population of 7.1% from a previous study on the "burden of serious fungal infection" conducted in Tanzania[6], the confidence level of 95% (z = 1.96) and precision (d) of 5%,. On data collection, a total of 405 PLHIV on TLD admitted to the medical wards from 2019 to 2022 files were retrieved in the three visited RRHs.

100

## D. Data collection

An Excel spreadsheet was used to collect data from patients' files, laboratory test results, and Care 101 and Treatment Clinic (CTC) cards where sections involving treatment practice and associated 102 factors were included, as information about associated risk factors, treatment practice, and 103 prevalence was obtained. The information was collected with the assistance of the respected 104 facility's responsible healthcare worker. On days of data collection data collectors were given files 105 106 of the HIV patients admitted in medical wards from 2019 to 2022 from the archives. To observe confidentiality names and other information which could identify the participant were not 107 documented. 108

It is made available under a CC-BY 4.0 International license .

#### 109 E. Data analysis

Data obtained was analyzed by using Statistical Package for Social Science (SPSS) software, version 23. Descriptive statistics was used to summarize socio-demographic and clinical characteristics; the Chi-square test was used to analyze variables associated with the prevalence of CM and treatment outcomes among those who tested CM positive. A p-value below 0.05 was considered statistically significant.

115 F. Ethical issues

Ethical clearance was obtained from the Muhimbili University of Health and Allied Sciences 116 (MUHAS)- Research Ethics Committee (REC). The protocol stated clear that the study will 117 retrieve information from patients medical records and the clearance was issued MUHAS-REC: 118 Ref. No. DA. 283/298/01L/602). Permission from the three RRHs administrations (Temeke, 119 Amana, and Mwananyamala) was sought before data collection. Patients' files were obtained from 120 121 medical file archives and special identification number was assigned for each file to protect confidentiality of the participants information. Participants name and another information that 122 could identify the participants were not abducted from the files. 123

124 III. Results

A.

#### 125

### Demographic characteristics of study participants

Out of 405 participants, the majority 224 (55.3%) were between 36-55 years followed by 98(24.2%), 18-35 years of age. Regarding employment status, the majority 167(41.2%) were selfemployed and 293(72.3%) were married. Besides, most 267(65.9%) of the participants were female and 37(9.1%) were ART defaulter(**table1**).

130 *Table 1: Demographic characteristics of study participants (n=405)* 

It is made available under a CC-BY 4.0 International license .

Variables	Median (Range)	n(%)	
Age (years)	43 (2-78) years		
Age category (years)			
<18		28(6.9)	
18-35		98(24.2)	
36-55		224(55.3)	
>55		55(13.6)	
Sex			
Female		267 (65.9)	
Male		138 (34.1)	
Occupation			
Employed		150(37.0)	
Self-employed		167(41.2)	
Unemployed		88(21.7)	
Marital status			
Married		293(72.3)	
Unmarried		112(27.7)	
ART Defaulter			
Yes		37(9.1)	
No		368(90.9)	

It is made available under a CC-BY 4.0 International license .

# B. Prevalence of CM, CD4 count at diagnosis, treatment approach and Outcome of treatment among participants

- 134 Out of 405 participants, 48 (11.9%) tested CM positive. Of those who tested positive, 6(12.5%)
- 135 received triple therapy (fluconazole, 5FC, and amphotericin) while 42(87.5%) received
- fluconazole alone. Following treatment, 4(8.9%) died, 18(40%) recovered, 17(37.8%) were lost to
- follow-up, 2(4.4%) were given referral, and 4(8.9%) were on going with treatment (table 2).
- 138 *Table 2: Prevalence of cryptococcal meningitis, CD4 count at diagnosis, treatment approach, and*
- 139 *Outcome of treatment among participants (n=405)*

Variable	n(%)
Cryptococcal meningitis status (n =405)	
Positive	48(11.9)
Negative	357(88.1)
CD4 count (cells/µL) at diagnosis Cryptococcal meningitis (n =48)	
<200	39(81.3)
≥200	9(18.8)
Treatment regimen used (n=48)	
flu, 5FC, and amphotericin B	6(12.5)
fluconazole	42(87.5)
Treatment Outcomes (n=45)	
Died	4(8.9)
Recovered	18(40)
Loss To Follow up	17(37.8)

It is made available under a CC-BY 4.0 International license .

Referred	2(4.4)
On treatment	4(8.9)

140

## 141 C. Factors associated with CM status among study participants

Following Pearson chi-square test, all 37 (100%) ART defaulters tested CM positive compared to non-defaulters; the difference was statistically significant (p-value < 0.01). While those unmarried 24(21.4%) significantly (p-value < 0.01) tested CM positive compared to those who are in marriage 24(8.1%). Other factors including age, sex, and occupation were not associated with being CM-positive among the participants (**table 3**).

147 Table 3: Showing Pearson chi-square test of the demographic characteristics and Cryptococcal

148 *meningitis status among participants (n = 405)* 

Variables	Cryptococcal m	Cryptococcal meningitis status		
Age (years)	Positive	Negative		
Age category (years)				
<18	0(0.0)	28(100)		
18-35	17(17.3)	81(82.7)		
36-55	25(11.2)	199(88.8)	0.80	
>55	6(10.9)	49(89.1)		
Sex				
Female	23(16.7)	115(83.3)		
Male	25(9.4)	242(90.6)	0.31	
Occupation				

It is made available under a CC-BY 4.0 International license .

8(9.1)	80(90.9)		
20(13.2)	132(86.8)	0.64	
20(12.1)	145(87.9)		
24(8.2)	269(91.8)		
24(21.4)	88(78.6)	< 0.01	
37(100)	0(0.0)		
11(3.0)	357(97.0)	< 0.01	
	20(13.2) 20(12.1) 24(8.2) 24(21.4) 37(100)	20(13.2)       132(86.8)         20(12.1)       145(87.9)         24(8.2)       269(91.8)         24(21.4)       88(78.6)         37(100)       0(0.0)	

149

# 150D. Factors associated with Cryptococcal meningitis treatment outcomes among151study participants

Among those who were given a recommended regimen none died, none neither had loss to follow 152 up nor referral, 3(60.0%) recovered and 2(40%) were on going with treatments while among those 153 given fluconazole alone; 4(10%) died, 15(37.5%) recovered, 17(42.5%) were loss to follow up, 154 2(5%) were referred and 2(5%) are ongoing with treatment and the difference were slightly 155 significant (p-value = 0.048). Other factors like age, sex, occupation, marital status, ART defaulter 156 157 status, and CD4 count at the time of diagnosis were not statistically related to CM treatment 158 outcome. However, for those who had a CD4 count < 200 cells/µL at the time of diagnosis, 4 (11.1%) died, and 12(33.3%) recovered while those who had a CD4 count of  $\geq$ 200 cells/µL none 159 died, 6(66.7%) recovered (table 4) 160

Table 4: Showing Pearson chi-square test of the demographic characteristics and Cryptococcal
 meningitis status among participants (n=45)

It is made available under a CC-BY 4.0 International license .

Variable	Treatment Outcomes n (%)					
	Died	Recovere	Loss To Follow	Referred	On	
		d	up		treatment	
Age category						
<18	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0(0.0)	
18-35	0(0.0)	7(46.7)	7(46.7)	1(6.7)	0(0.0)	0.31
36-55	2(8.3)	10(41.7)	8(33.3)	1(4.2)	3(12.5)	_
>55	2(33.3)	1(16.7)	2(33.3)	0(0.0)	1(16.7)	_
Sex			<u> </u>			
Male	3(14.3)	9(42.9)	7(33.3)	1(4.8)	1(4.8)	
Female	1(4.2)	9(37.5)	10(41.7)	1(4.2)	3(12.5)	0.68
Occupation						
Unemployed	0(0.0)	2(28.6)	4(57.1)	1(14.3)	0(0.0)	
Employed	1(5.0)	7(35.0)	10(50.0)	0(0.0)	2(10.0)	0.28
Self employed	3(16.7)	9(50.0)	3(16.7)	1(5.6)	2(11.1)	_
Marital status						
Married	3(13.6)	11(50.0)	7(31.8)	0(0.0)	1(4.5)	
Unmarried	1(4.3)	7(30.4)	10(43.5)	2(8.7)	3(13.0)	0.25
ART defaulter						
Yes	3(8.8)	14(41.2)	12(35.3)	1(2.9)	4(11.8)	0.69
No	1(9.1)	4(36.4)	5(45.5)	1(9.1)	0(0.0)	
CD4 count at dia	gnosis (cells	⊥ s/µL)	I	<u> </u>	1	
<200	4(11.1)	12(33.3)	15(41.7)	2(5.6)	3(8.3)	

It is made available under a CC-BY 4.0 International license .

≥200	0(0.0)	6(66.7)	2(22.2)	0(0.00)	1(11.1)	0.37
Treatment regim	ien	1				
Flu,5FC,	0(0.0)	3(60.0)	0(0.0)	0(0.0)	2(40.0)	
amphotericin						0.048
Fluconazole	4(10.0)	15(37.5)	17(42.5)	2(5.0)	2(5.0)	

163

### 164 IV. Discussion

The objective of this study was to determine the prevalence, treatment, and factors associated with 165 CM post-introduction of TLD regimen among PLHIV in Tanzania. Out of 405 reviewed patient 166 files, the study found that 11.9% had CM, out of which 12.5% received the recommended regimen 167 (triple therapy = Fluconazole, 5-FC, and amphotericin B) and 87.5% received fluconazole alone. 168 Following treatment, 40% recovered while 37.8% were lost to follow-up. ART defaulter and 169 marital status were significantly associated with those who tested CM positive; neither of those 170 treated with triple therapy died, referred, or lost to follow-up compared to those on fluconazole 171 172 alone.

The prevalence observed in our study is comparable to what was observed in developing countries like Cameroon (11.2%), and Ethiopia (11.4%) [21,22]. The reported prevalence is slightly higher than what was observed in Sierra Leone (7.7%) and Indonesia (7.1%) and higher than what was reported in London (5%), Nigeria (5.1%) and Haiti (1.1%) [23,24]. Varying prevalence's of CM were observed in different studies could be due to the type of the study design and data collection approaches. Also, some studies included all naive and experienced PLHIV patients while others recruited only those on ART for some time. Our studies assess the CM status of the PLHIV

It is made available under a CC-BY 4.0 International license .

admitted in the hospital for medical reasons which could explain the observed high prevalence.
Nevertheless, differences in laboratory protocol, healthcare system, and geographical location of
the study settings have been associated with the inconsistency of the reported CM prevalence
among PLHIV [25,26]. Since CM is acquired through inhalation of the yeast droplet from the air,
weather condition differences may also influence the reported prevalence.

185 The study demonstrated that only 12.5% of those with CM were treated with the recommended regimen which is a combination of Amphotericin B and 5-FC during the induction course and 186 Fluconazole during the completion phase. The uses of Amphotericin B and flucytosine are reported 187 188 to reduce CM-related mortality by 40% and clinical trials report that the use of fluconazole alone in the management of CM is inferior [16]. Similar to findings from this study PLHIV with CM 189 treated with fluconazole alone, the majority died or were lost to follow-up compared to those given 190 triple therapy. Despite being recommended by WHO and adopted by member countries like 191 Tanzania, the use of triple therapy in the management of CM in most of the developing countries 192 is low [27]. The poor availability of 5-FC and amphotericin B and the associated cost of purchasing 193 the two medications could be a reason for their poor use in developing countries [28]. The use of 194 a drug like amphotericin B requires laboratory tests prior to and during the time of using the drug 195 196 in order to prevent patients from toxicity [29]. The latter increases the cost of treatment, taking into consideration that the majority of people in developing countries rely on out-of-pocket mode 197 of payment and the level of poverty could be a reason why healthcare providers (HCPs) opt to use 198 fluconazole alone [30]. 199

In addition, triple therapy involves a different route of drug administration, as fluconazole and 5-FC are given by infusion, and amphotericin B is given intrathecally. The competency of administering amphotericin B among HCPs and the complexity of monitoring for toxicity could

be another reason why most HCPs opt for the use of fluconazole alone [31]Training of the HCPs 203 and people involved in the care of PLHIV on how to use triple therapy should be in place to equip 204 HCPs with knowledge and skills on how to dose and administer the medications [28]. 205 Nevertheless, in Tanzania, as in other developing countries patients appear late in the hospital and 206 PLHIV with CM end up admitted and treated as an inpatient through a medical ward. However, 207 208 medicines and consumables for PLHIV which are purchased and sent to the facilities through a vertical program are available in the CTC. Therefore, proper communication should be initiated to 209 ensure PLHIV admitted in the wards receive medications from CTC. The latter will foster the use 210 211 of triple therapy as fluconazole, 5-FC, and amphotericin B are grouped as drugs for opportunistic infections (OIs) and are procured through vertical programs [29,32]. 212

The study also observed that ART defaulters were significantly associated with those who tested 213 CM positive. The findings are consistent with what has been reported repeatedly that stopping the 214 use of ART leads to increased viral load, suppressing CD4 cells, and exposing patients to OIs like 215 CM. HIV infection is the common risk of CM, as the risk is estimated to be 95% in PLHIV living 216 in middle-low-income countries and 80% in high-income countries. Despite TLD being effective 217 and user-friendly, current studies still report inadequate adherence to ART among PLHIV [33.34]. 218 Although WHO recommends screening for CM to PLHIV with CD4 levels < 100/ul and naive, 219 studies report the significant prevalence of CM among ART-experienced patients. To fight against 220 the deadly disease, screening for CM among PLHIV should be done regularly despite the CD4 221 222 level and years of being on ART [18]. Furthermore, the use of fluconazole as prophylaxis should be scaled up to all PLHIV, particularly in developing countries where the majority have immune 223 problems and access to medical care is a challenge [35]. The latter is possible by taking the 224

It is made available under a CC-BY 4.0 International license .

example of Isoniazid prophylaxis therapy (IPT) for the prevention of tuberculosis among PLHIV[19].

227 The study found that the prevalence of CM was higher among unmarried people compared to 228 married people. Several studies report the importance of PLHIV having a close relative/friend or spouse be aware of his/her status [36,37]). Advantages of disclosing HIV status include reducing 229 230 the level of stigma, having someone to remind a patient to take medication, and clinic schedules and it improves the quality of living [38]. Therefore, more efforts should be implemented to ensure 231 that the majority of PLHIVs disclose the status at least to one of the close spouses/relative or friend. 232 233 Moreover, our study found no significant difference in CM prevalence between males and females. The findings are not similar to what was reported in other studies in which the prevalence of CM 234 was high in males compared to females [20]. The difference observed could be due to the study 235 setting; our study was conducted in the city of Dar es Salaam, in which both men and women are 236 considered breadwinners of the family [39]. Therefore, being outdoors both men and women are 237 equally exposed to contaminated environments. 238

#### 239 V. Conclusion

The study found the prevalence of CM among PLHIV to be significantly high. Unlike the guideline recommendation, the majority of PLHIV with CM were treated with fluconazole alone instead of triple therapy. ART defaulters and marital status were significantly associated with one being CM positive. Responsible authorities and stakeholders should enforce guideline adherence and a mechanism should be instituted to ensure PLHIV adheres to medication. Taking an example of tuberculosis treatment, in which a victim must visit the clinic with a relative, strategies should be proposed to ensure PLHIV discloses their status to at least a spouse/relative or a close friend.

It is made available under a CC-BY 4.0 International license .

#### 247 VI. List of abbreviation

- 5-FC: 5-fluorocytosine(Flucytosine), ART: Antiretroviral Therapy, CTC: Care and Treatment
  Centre, CD4: Clusters of Differentiation 4, CM: Cryptococcal meningitis, PLHIV: People Living
  With Human Immunodeficiency Virus, HIV: Human Immunodeficiency Virus, HCPs: Health
  Care Providers, IPT: Isoniazid Prophylaxis Therapy, LIC: Lower Income Countries, MUHAS:
  Muhimbili University of Health and Allied Sciences, RRH: Regional Referral Hospitals, SPSS:
  Statistical Package for Social Science, TLD: Tenofovir Lamivudine Dolutegravir
- 254 VII. Acknowledgements

The authors sincerely thank the Muhimbili University of Health and Allied Sciences – Research and Ethics Committee (MUHAS-REC) for providing ethical clearance and administration of the visited hospitals for providing permission to conduct data collection. We also thank each appointed hospital HCP who helped data collectors to retrieve files and clarified some of the unexplained information.

#### 260 VIII. References

- Kisenge PR, Hawkins AT, Maro VP, Mchele JPD, Swai NS, Mueller A, et al. Low CD4
   count plus coma predicts cryptococcal meningitis in Tanzania. BMC Infect Dis. 2007;7: 1–
   5. doi:10.1186/1471-2334-7-39.
- Britz E, Perovic O, Von Mollendorf C, Von Gottberg A, Iyaloo S, Quan V, et al. The
   epidemiology of meningitis among adults in a south African province with a high HIV
   prevalence. 2009-2012. PLoS One. 2016;11: doi:10.1371/journal.pone.0163036.
- 267 3. Muzazu SGY, Assefa DG, Phiri C, Getinet T, Solomon S, Yismaw G, et al. Prevalence of

It is made available under a CC-BY 4.0 International license .

- cryptococcal meningitis among people living with human immuno-deficiency virus and
   predictors of mortality in adults on induction therapy in Africa: A systematic review and
   meta-analysis. Front Med. 2022;9: 1–13. doi:10.3389/fmed.2022.989265
- 4. Radha Rajasingham, Rachel M Smith, Benjamin J Park, Joseph N Jarvis, Nelesh P
   Govender, Tom M Chiller et al. Global burden of disease of HIV-associated cryptococcal
   meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873-881. doi:
   10.1016/S1473-3099(17)30243-8.
- 5. Faini D, Maokola W, Furrer H, Hatz C, Battegay M, Tanner M, et al. Burden of serious
  fungal infections in Tanzania. Mycoses. 2015;58: 70–79. doi:10.1111/myc.12390.
- 277 6. Teekaput C, Yasri S, Chaiwarith R. Cryptococcal Meningitis: Differences between Patients
  278 with and without HIV-Infection. Pathogens. 2023;12. doi:10.3390/pathogens12030427.
- Baddley JW, Schain DC, Gupte AA, Lodhi SA, Kayler LK, Frade JP, et al. Transmission
   of Cryptococcus neoformans by organ transplantation. Clin Infect Dis. 2011;52: 94–98.
   doi:10.1093/cid/ciq216.
- Joel Schop. Protective immunity against cryptococcus neoformans infection. McGill J Med.
   2007;10: 35–43. doi:10.26443/mjm.v10i1.467.
- 9. Ngan NTT, Flower B, Day JN. Treatment of Cryptococcal Meningitis: How Have We Got
  Here and Where are We Going? Drugs. 2022;82: 1237–1249. doi:10.1007/s40265-02201757-5
- 10. NASP. National Guidelines for the Management of HIV and AIDS. Development. 2019;7:
  2,274,923,575.

It is made available under a CC-BY 4.0 International license .

- 289 11. Calmy A, Tovar Sanchez T, Kouanfack C, Mpoudi-Etame M, Leroy S, Perrineau S, et al.
- 290 Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1
- 291 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open
- label, phase 3 non-inferiority trial in Cameroon. Lancet HIV. 2020;7: e677–e687.
- doi:10.1016/S2352-3018(20)30238-1
- de Faria Ferreira M, Brito-Santos F, Henrique Nascimento Theodoro P, de Abreu Almeida
   M, Lazera M dos S, Trilles L. Mixed infection by Cryptococcus neoformans and
   Cryptococcus gattii and coinfection with paracoccidioidomycosis in PLHIV. Med Mycol
   Case Rep. 2022;35: 48–50. doi:10.1016/j.mmcr.2022.01.006
- Ouedraogo D, Cissoko Y, Soumare M, Alle Akakpo AE, Loua O-O, Konate I, et al.
  Neuromeningeal Cryptococcosis and Tuberculosis Coinfection in Bamako: A One-Year
  Case Series. Open Forum Infect Dis. 2023;10: 1–4. doi:10.1093/ofid/ofad438
- 14. Perfect JR, Dismukes WE, Dromer F, Goldman DL, John R, Hamill RJ, et al. Guideline for
  cryptococcus. Clin Infect Dis. 2018;50: 291–322. doi:10.1086/649858.Clinical
- Miot J, Leong T, Takuva S, Parrish A, Dawood H. Cost-effectiveness analysis of flucytosine
  as induction therapy in the treatment of cryptococcal meningitis in HIV-infected adults in
  South Africa. BMC Health Serv Res. 2021;21: 1–11. doi:10.1186/s12913-021-06268-9
- 16. Loyse A, Dromer F, Day J, Lortholary O, Harrison TS. Flucytosine and cryptococcosis:
  Time to urgently address the worldwide accessibility of a 50-year-old antifungal. J
  Antimicrob Chemother. 2013;68: 2435–2444. doi:10.1093/jac/dkt221
- 309 17. Longley N, Muzoora C, Taseera K, Mwesigye J, Rwebembera J, Chakera A, et al. Dose

It is made available under a CC-BY 4.0 International license .

	response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in
	southwestern Uganda. Clin Infect Dis. 2008;47: 1556–1561. doi:10.1086/593194
18.	Abassi M, Boulware DR, Rhein J. Cryptococcal Meningitis: Diagnosis and Management
	Update. Curr Trop Med Reports. 2015;2: 90–99. doi:10.1007/s40475-015-0046-y
19.	Hailu K, Niguse S, Hagos K, Abdulkader M. Cryptococcal antigenemia and associated risk
	factors among ART-naïve and ART-experienced HIV-infected peoples at selected health
	institutions of Mekelle, Northern Ethiopia. Microbiologyopen. 2019;8: 1-8.
	doi:10.1002/mbo3.746
20.	Negash M, Wondmagegn T, Tajebe F. Opportunistic Cryptococcal Antigenemia in the
	HAART Era at HIV Epidemic Settings of Northwest Ethiopia. Can J Infect Dis Med
	Microbiol. 2020;2020. doi:10.1155/2020/5017120
21.	Jemal M, Deress T, Belachew T, Adem Y. Prevalence of Cryptococcal Antigenemia and
	Associated Factors among HIV / AIDS Patients at Felege-Hiwot Referral Hospital, Bahir
	Dar, Northwest Ethiopia. 2021;2021.
22.	Luma HN, Temfack E, Halle MP, Nguenkam Tchaleu BC, Mapoure YN, Koulla-Shiro S.
	Cryptococcal meningoencephalitis in human immunodeficiency virus/acquired
	immunodeficiency syndrome in Douala, Cameroon: A cross sectional study. N Am J Med
	Sci. 2013;5: 486-491. doi:10.4103/1947-2714.117318
23.	Lakoh S, Rickman H, Sesay M, Kenneh S, Burke R, Baldeh M, et al. Prevalence and
23.	Lakoh S, Rickman H, Sesay M, Kenneh S, Burke R, Baldeh M, et al. Prevalence and mortality of cryptococcal disease in adults with advanced HIV in an urban tertiary hospital
	<ul><li>19.</li><li>20.</li><li>21.</li></ul>

It is made available under a CC-BY 4.0 International license .

- 331 020-4862-x
- 332 24. Geda N, Beyene T, Dabsu R, Mengist HM. Prevalence of Cryptococcal Antigenemia and associated factors among HIV/AIDS patients on second-line antiretroviral therapy at two 333 Oromia. in Western Ethiopia. PLoS 2019;14: 334 hospitals One. 1 - 13. doi:10.1371/journal.pone.0225691 335
- 25. Mollov SF, Chiller T, Greene GS, Burry J, Govender NP, Kanyama C, et al. Cryptococcal 336 NTD? meningitis: neglected PLoS Negl Dis. 2017:11: 337 А Trop 1-7.338 doi:10.1371/journal.pntd.0005575
- Kaplan JE, Vallabhaneni S, Smith RM, Chideya-Chihota S, Chehab J, Park B. Cryptococcal
  antigen screening and early antifungal treatment to prevent cryptococcal meningitis: A
  review of the literature. J Acquir Immune Defic Syndr. 2015;68: S331–S339.
  doi:10.1097/QAI.00000000000484
- 343 27. WHO. Guidelines for the diagnosis, prevention and management of cryptococcal disease.344 2018.
- 28. Loyse A, Burry J, Cohn J, Ford N, Chiller T, Ribeiro I, et al. Leave no one behind: response
  to new evidence and guidelines for the management of cryptococcal meningitis in lowincome and middle-income countries. Lancet Infect Dis. 2019;19: e143–e147.
  doi:10.1016/S1473-3099(18)30493-6
- Molloy SF, Kanyama C, Heyderman RS, Loyse A, Kouanfack C, Chanda D, et al.
  Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. N Engl J
  Med. 2018;378: 1004–1017. doi:10.1056/nejmoa1710922

It is made available under a CC-BY 4.0 International license .

- 352 30. Kitole FA, Lihawa RM, Mkuna E. Equity in the public social healthcare protection in
  353 Tanzania: does it matter on household healthcare financing? Int J Equity Health. 2023;22:
- 354 1–14. doi:10.1186/s12939-023-01855-0
- 355 31. Cavassin FB, Baú-Carneiro JL, Vilas-Boas RR, Queiroz-Telles F. Sixty years of
   356 Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal
   357 Infections. Infect Dis Ther. 2021;10: 115–147. doi:10.1007/s40121-020-00382-7
- 358 32. isangula KG. Prevention of Mother to Child Transmission of HIV Program in Tanzania:
  359 Service Delivery and Uptake Constraints. SSRN Electron J. 2012.
  360 doi:10.2139/ssrn.1976890
- 361 33. Kilapilo MS, Sangeda RZ, Bwire GM, Sambayi GL, Mosha IH, Killewo J. Adherence to
  362 Antiretroviral Therapy and Associated Factors Among People Living With HIV Following
  363 the Introduction of Dolutegravir Based Regimens in Dar es Salaam, Tanzania. J Int Assoc
  364 Provid AIDS Care. 2022;21: 1–8. doi:10.1177/23259582221084543
- 34. Alufandika M, Lawrence DS, Boyer-Chammard T, Kanyama C, Ndhlovu CE, Mosepele M,
  et al. A pragmatic approach to managing antiretroviral therapy-experienced patients
  diagnosed with HIV-associated cryptococcal meningitis: Impact of antiretroviral therapy
  adherence and duration. Aids. 2020;34: 1425–1428. doi:10.1097/QAD.0000000002556
- 35. Katende A, Mbwanji G, Faini D, Nyuri A, Kalinjuma AV, Mnzava D, et al. Short-course 369 370 amphotericin B in addition to sertraline and fluconazole for treatment of HIV-associated cryptococcal meningitis in rural Tanzania. Mycoses. 2019;62: 1127–1132. 371 372 doi:10.1111/myc.12995

It is made available under a CC-BY 4.0 International license .

- 373 36. Xu JF, Ming ZQ, Zhang YQ, Wang PC, Jing J, Cheng F. Family support, discrimination,
- and quality of life among ART-treated HIV-infected patients: A two-year study in China.
- 375 Infect Dis Poverty. 2017;6: 1–10. doi:10.1186/s40249-017-0364-5
- 376 37. Banagi Yathiraj A, Unnikrishnan B, Ramapuram JT, Kumar N, Mithra P, Kulkarni V, et al.
- Factors Influencing Adherence to Antiretroviral Therapy among People Living with HIV in
- 378 Coastal South India. J Int Assoc Provid AIDS Care. 2016;15: 529–533.
  379 doi:10.1177/2325957416661424
- 38. Hallberg D, Kimario TD, Mtuya C, Msuya M, Björling G. Factors affecting HIV disclosure
  among partners in Morongo, Tanzania. Int J Africa Nurs Sci. 2019;10: 49–54.
  doi:10.1016/j.ijans.2019.01.006
- 383 39. Ezeanolue EE, Nwizu C, Greene GS, Amusu O, Chukwuka C, Ndembi N, et al. Brief
- Report: Geographical Variation in Prevalence of Cryptococcal Antigenemia among HIV-
- 385 Infected, Treatment-Naive Patients in Nigeria: A Multicenter Cross-Sectional Study. J
- 386 Acquir Immune Defic Syndr. 2016;73: 117–121. doi:10.1097/QAI.000000000001048